MedPath

Placebo Effects on Blood Pressure

Not Applicable
Conditions
Blood Pressure
Interventions
Other: Placebo with BP inc (written)
Other: Placebo with BP dec (doctor)
Other: Placebo with BP dec (written form)
Other: Placebo info given (doc)
Other: Placebo with BP inc (doctor)
Other: Placebo info given (written)
Registration Number
NCT00570271
Lead Sponsor
Charite University, Berlin, Germany
Brief Summary

A relevant reduction of blood pressure (BP) in placebo-treated control groups is a phenomenon often observed in pharmacological studies of hypertension. This effect was shown to differ from spontaneous remission tendencies and regression to the mean effect by comparing placebo groups with untreated controls. However, it is not fully understood whether these effects are due to a global reaction of the autonomous nervous system (affecting the overall organ systems of the body) or a specific reaction (affecting the cardiovascular system only). We therefore aim to differentiate specific effects (reduction of blood pressure) from global effects (e.g. changes in electrodermal and gastric activity).

In our study we aim to test the following hypotheses:

1. Placebo administration leads to a significant changes of blood pressure compared with untreated controls.

2. The direction of blood pressure change depends on the type of suggestion (either decrease or increase)

3. This effect is specific for blood pressure; changes in electrodermal and gastric activity do not differ between groups.

4. The placebo response can be enhanced by a prestige intervention (information about the suggested drug action given by doctor or in written form).

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
90
Inclusion Criteria
  • Informed consent
Exclusion Criteria
  • Not meeting inclusion criteria
  • Untreated hypertension (BP > 140/90) or hypotension(BP < 100/60)
  • Severe systemic disorders (tumors, tbc, diabetes, asthma etc)
  • Diseases with influence on cardiovascular or gastrointestinal system
  • Pregnancy and lactation phase
  • Body mass index > 30
  • Regular intake of drugs with influence on the autonomic nervous system
  • Insufficient compliance
  • Simultaneous participation in another trial

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
3Placebo with BP inc (written)-
2Placebo with BP dec (doctor)-
1Placebo with BP dec (written form)-
6Placebo info given (doc)-
4Placebo with BP inc (doctor)-
5Placebo info given (written)-
Primary Outcome Measures
NameTimeMethod
Mean arterial pressure60 minutes
Secondary Outcome Measures
NameTimeMethod
Heart rate60 minutes
skin conductance level60 minutes
gastric activity60 minutes

Trial Locations

Locations (1)

Department of Psychosomatic Medicine and Psychotherapy, Charité University

🇩🇪

Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath